Flyer

Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 61
  • Journal CiteScore: 17.30
  • Journal Impact Factor: 18.23
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
Share This Page

An Innovative Community Based Model of Care among PWID in Napoli 2 Area

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

D’Antò M, Luiso V, Cuomo V and Ranucci RAN

UOC Internal Medicine, P.O.â�?S.Maria delle Grazieâ�?, Pozzuoli (NA), Italy
UOC Emergency Medicine, Az. Osp. Dei Colli, Napoli, Italy

Posters & Accepted Abstracts: Health Sci J

Abstract:

Background and aims: The linkage to care of PWID still remains an important gap in HCV treatment in Southern Italy in particular during pandemic. We evaluated a new model of care to improve the LTC throughout a pathway simplification and decentralization of HCV care with a close collaboration with addiction centers and hospital specialist and use of remote monitoring. Patients and methods: The project started from January 2019 and it is currently ongoing. Four addiction centers of Naples district were involved (Acerra, Pozzuoli, Giugliano, Casavatore). A complete hepatological assessment, including blood chemistry, ultrasound and transient elastography examination, was provided. Hospital specialist confirmed diagnosis and prescribed DAA by visit on site before pandemic and by remote engagement during pandemic. Results: 500 patients were screened, 300 were positive and 200 were treated; 87% were active drugs users and 79% of them were receiving opioid substitution therapy; 30% presented genotype 1a, the 36% 1b and 28% 3a. Everyone was treated with DAAs regimens. Discussion: The SVR was 99% and remote monitoring through phone and video calls was successful.